Market Cap$49.86B
P/E46.50x
PEG Ratio1.85
Div yield—
Beta0.84
EW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.84%
Price vs S&P 500 (4W)-0.64%
PEG Ratio1.85
VGM Score48.03
P/E Ratio (Annual)46.50x
EW Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.74 | $0.78 | +5.11%(+$0.04) | |
| Q1 2026 | $0.73 | $0.78 | +7.33%(+$0.05) | |
| Q4 2025 | $0.62 | $0.58 | -6.27%(-$0.04) | |
| Q3 2025 | $0.59 | $0.67 | +12.63%(+$0.08) | |
| Q2 2025 | $0.62 | $0.67 | +7.64%(+$0.05) |
EW Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.02
4.00
4.08
4.10
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
| AVRAnteris Technologies Global Corp. Common Stock | D | C | C | 263.0x | — | 75.0% | -4738.4% | $6.05 |
About Edwards Lifesciences Corp
Edwards Lifesciences is a global leader in medical devices for treating structural heart disease, specializing in surgical tissue heart valves and transcatheter valve replacement technologies. Spun off from Baxter International in 2000, the company has established dominant market positions across aortic, mitral, and tricuspid valve solutions. With approximately 60% of revenues from international markets, Edwards benefits from strong geographic diversification in the growing structural heart disease treatment sector.